TCP
LRMR icon

Tourbillon Capital Partners’s Larimar Therapeutics LRMR Stock Holding History

Tourbillon Capital Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-38,230
Closed -$14.7M – 84
2015
Q3 		$14.7M Buy
+38,230
New +$17.2M 0.38% 58

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Tourbillon Capital Partners's LRMR Position: Q4 2015 in Review

Tourbillon Capital Partners sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 38,230 shares — an estimated $14.7M sold.

Tourbillon Capital Partners first reported a position in LRMR in Q3 2015 and held it in 1 quarter. The position peaked at $14.7M in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Tourbillon Capital Partners reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Tourbillon Capital Partners sold 38,230 Larimar Therapeutics shares in Q4 2015, an estimated $14.7M.
  • Tourbillon Capital Partners first reported a position in Larimar Therapeutics in Q3 2015 and held it in 1 quarter.
  • Tourbillon Capital Partners's Larimar Therapeutics position peaked at $14.7M in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Tourbillon Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.